MedTrace Logo

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

NCT05599048 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-03-24

No results posted yet for this study

Summary

This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

Hyperpolarized 13C-Pyruvate

Given IV

PROCEDURE

Magnetic Resonance Imaging (MRI)

Imaging procedure

DRUG

13C,15N-Urea

Given IV

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sigma-Aldrich

    collaborator UNKNOWN

  • Robert Bok, MD, PhD

    lead OTHER

Principal Investigators

  • Robert Bok, MD, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599048 on ClinicalTrials.gov